Sta Znaci RECEIVING CONCOMITANT na Hrvatskom - Hrvatski Prijevod

• istodobno primaju
• istovremeno primaju
• primaju istodobno
• istodobno primali
• istodobno dobivali

Primjeri korištenja Receiving concomitant na Engleski i njihovi prijevodi na Hrvatskom

Patients receiving concomitant administration of monoamine oxidase inhibitors MAOI.
Bolesnici koji primaju istodobno inhibitore monoaminooksidaze MAOI.

Responses were similar in patients who were or were not receiving concomitant therapies at baseline.
Odgovori su bili slični kod bolesnika bez obzira na to jesu li na početku istodobno primali neku drugu terapiju.

Patients receiving concomitant NSAIDs and conventional DMARDs were 72.6% and 70.2% respectively.
Odnosno 70,2% bolesnika je istodobno primalo NSAIL-e odnosno konvencionalne DMARD-e.

Rare cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.
U bolesnika koji su istodobno primali radioterapiju, zabilježeni su rijetki slučajevi radijacijskog pneumonitisa.

Patients receiving concomitant treatment with quinidine, quinine, or mefloquine see section 4.5.
Bolesnici koji istovremeno primaju terapiju kinidinom, kininom ili meflokinom vidjeti dio 4.5.

There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Povećan je rizik aritmija u bolesnika koji istodobno primaju anesteziju halogeniranim ugljikovodicima.

Patients receiving concomitant glucocorticoid therapy should have their dose carefully adjusted.
Bolesnicima koji istovremeno primaju terapiju glukokortikoidima moraju se pažljivo prilagoditi doze.

There is no experience of the use of delamanid in patients receiving concomitant therapy against HIV see section 4.5.
Nema iskustva o primjeni delamanida u bolesnika koji istodobno primaju terapiju protiv HIV-a vidjeti dio 4.5.

In patients receiving concomitant antihypertensive medicinal products, tadalafil may induce a blood pressure decrease.
U bolesnika koji istodobno primaju antihipertenzive tadalafil može izazvati sniženje krvnog tlaka.

Two additional pivotal trials(SP650DB and SP515) were conducted in patients who were receiving concomitant levodopa therapy.
Provedena su još dva dodatna pivotalna istraživanja(SP650DB i SP515) u bolesnika koji su istovremeno primali terapiju levodopom.

Patients receiving concomitant glucocorticoid therapy should have their dose carefully adjusted to avoid an inhibitory effect on growth.
Bolesnicima koji istovremeno primaju terapiju glukokortikoidima moraju se pažljivo prilagoditi doze kako bi se izbjegao inhibirajući učinak na rast.

In addition, the risk of seizure may be increased in patients receiving concomitant medicinal products that lower the seizure threshold.
Osim toga, rizik od napadaja može biti povećan u bolesnika koji istovremeno primaju lijekove koji snižavaju prag za napadaje.

In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply see section 4.5.
U bolesnika koji istodobno primaju sistemsku terapiju snažnim induktorima CYP3A4 i P-gp primjenjuju se sljedeće preporuke vidjeti dio 4.5.

No dose adjustment is considered necessary for administration of ulipristal acetate to patients receiving concomitant mild CYP3A4 inhibitors.
Prilagodba doze ne smatra se nužnom pri primjeni ulipristalacetata u bolesnica koje istovremeno primaju slabe inhibitore CYP3A4.

Patients receiving concomitant non-liposomal irinotecan and ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased SN-38 exposure by 109.
Bolesnici koji istodobno primaju neliposomalni irinotekan i ketokonazol, CYP3A4 i UGT1A1 inhibitor, imaju povećanje izloženosti metabolitu SN-38 od 109.

In postmarketing surveillance reported an increased risk in patients, receiving concomitant corticosteroids, especially over the age of 60 years.
U postmarketing nadzor ukazuju na povećani rizik u bolesnika, prima popratnim kortikosteroide, pogotovo u dobi od 60 godina.

Patients receiving concomitant treatment with thioridazine, a medicinal product that both significantly prolongs QT interval and is primarily metabolized by CYP2D6.
Bolesnici koji istovremeno primaju terapiju tioridazinom, lijekom koji i značajno produljuje QT interval i primarno je metaboliziran enzimom CYP2D6.

Treatment with Fexeric may lead to elevations in iron stores, particularly in patients receiving concomitant intravenous iron therapy.
Liječenje Fexericom može dovesti do povećanja zaliha željeza, osobito u bolesnika koji istodobno primaju terapiju intravenskim željezom.

HIV/HBV co-infected patients receiving concomitant HAART: study 038 included 67 HBeAg positive and 1 HBeAg negative patients co-infected with HIV.
Bolesnici istodobno inficirani HIV-om i HBV-om koji su istodobno primali HAART: ispitivanje 038 uključilo je 67 HBeAg pozitivnih i 1 HBeAg negativnog bolesnika istodobno inficiranih HIV-om.

Responses observed in the apremilast treated group were similar in patients receiving and not receiving concomitant DMARDs, including MTX.
Odgovori opaženi u skupini liječenoj apremilastom bili su slični u bolesnika koji jesu i onih koji nisu istodobno primali DMARD lijekove, uključujući metotreksat.

Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised see section 4.4.
Apiksaban se ne preporučuje u liječenju DVT i PE u bolesnika koji istodobno primaju sistemsku terapiju snažnim induktorima CYP3A4 i P-gp jer se može ugroziti djelotvornost vidjeti dio 4.4.

Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy.
Klinički značajna sniženja HbA1c u usporedbi s placebom s 25 mg alogliptina također su opažena bez obzira na to jesu li bolesnici istodobno primali terapiju metforminom ili sulfonilurejom.

HIV/HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in HIV/HBV co-infected patients not concurrently receiving effective HIV treatment.
Bolesnici istodobno inficirani HIV-om i HBV-om koji nisu istodobno primali HAART: entekavir se nije ispitivao u bolesnika istodobno inficiranih i HIV-om i HBV-om koji nisu istodobno primali učinkovito liječenje protiv HIV-a.

Fatal and non-fatal intracranial haemorrhage(ICH) have been reported in patients receiving tipranavir, many of whom had other medical conditions or were receiving concomitant medicinal products that may have caused or contributed to these events.
Fatalno i nefatalno intrakranijalno krvarenje(ICH) prijavljeno je u bolesnika na tipranaviru, od kojih su mnogi imali druga medicinska stanja ili su istodobno dobivali lijekove koji su možda izazvali ili doprinijeli ovim događajima.

Patients receiving concomitant parenteral aminoglycoside therapy(or any medicine affecting renal excretion, such as diuretics) should be monitored as clinically appropriate taking into account the risk of cumulative toxicity.
Bolesnike koji istodobno primaju aminoglikozid(ili bilo koji lijek koji utječe na bubrežno izlučivanje, kao što su diuretici) parenteralno moraju se odgovarajuće klinički pratiti uzimajući u obzir rizik od kumulativne toksičnosti.

Appropriate clinical and/or laboratory monitoring is recommended for patients receiving concomitant metformin and vandetanib, and such patients may require a lower dose of metformin.
Preporučuje se prikladno kliničko i/ili laboratorijsko praćenje za bolesnike koji primaju istodobno vandetanib i metformin, i takvim bolesnicima će možda biti potrebna niža doza metformina.

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based chemotherapy, or who have prior history of peptic ulceration or diverticular disease are at increased risk.
Bolesnici koji istovremeno primaju antiangiogene lijekove, kortikosteroide, nesteroidne protuupalne lijekove, i/ili kemoterapiju baziranu na taksanima, ili oni koji u anamnezi imaju peptične ulceracije ili divertikuloznu bolest, imaju povećani rizik.

When clinical information on the patients was available to make a judgement, approximately 50% of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.
U bolesnika kod kojih su bili dostupni klinički podaci za prosudbu, u otprilike 50% slučajeva rabdomioliza se javila u bolesnika s ranije prisutnim oštećenjem bubrega, ili u onih koji su istodobno primali lijekove za koje je poznato da izazivaju rabdomiolizu.

Patients receiving concomitant parenteral aminoglycoside therapy(or any medication affecting renal excretion, such as diuretics) should be monitored as clinically appropriate taking into account the risk of cumulative toxicity.
Bolesnike koji primaju istodobnu terapiju parenteralnim aminoglikozidom(ili bilo kojim lijekom koji utječe na bubrežno izlučivanje, kao što su diuretici) treba pratiti na klinički primjeren način uzimajući u obzir rizik od kumulativne toksičnosti.

FIRMAGON has not been studied in patients with a history of a corrected QT interval over 450 msec, in patients with a history of or risk factors for torsades de pointes and in patients receiving concomitant medicinal products that might prolong the QT interval.
FIRMAGON nije ispitan u bolesnika s korigiranim QT intervalom iznad 450 ms u anamnezi, u bolesnika s anamnezom ili čimbenicima rizika za torsades de pointes te u bolesnika koji su istovremeno primali lijekove koji bi mogli produljiti QT interval.